Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $5.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a report on Thursday, January 23rd.

Hoth Therapeutics Stock Performance

Shares of Hoth Therapeutics stock opened at $0.77 on Tuesday. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80. The company’s 50 day moving average price is $0.99 and its 200-day moving average price is $1.00. The stock has a market capitalization of $10.19 million, a price-to-earnings ratio of -0.59 and a beta of 0.64.

Hoth Therapeutics (NASDAQ:HOTH) last announced its quarterly earnings results on Thursday, March 27th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.07. As a group, equities research analysts forecast that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned approximately 0.47% of Hoth Therapeutics as of its most recent filing with the SEC. 7.08% of the stock is currently owned by institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.